Edward Hurwitz, a venture partner of Alta Partners, has joined the board of directors of Mountain View, Calif.-based Aclara Biosciences. From 1997 to 2001, he was senior vice president and CFO of Affymetrix. Hurwitz holds JD and MBA degrees from the University of California, Berkeley, and a BA in molecular biology from Cornell University.
Syrrx has hired two senior-level chemists, the company said last week. Jeffrey Stafford joins the company as senior director of chemistry, where he will be responsible for Syrrx''s discovery chemistry and medicinal chemistry programs, and Daniel Kassel will take on the position of senior director of ana-lytical technologies, reponsible for developing and implementing analytical and drug discovery technologies and ADME profiling of chemical leads. Stafford most recently served as director of chemistry in oncology at GlaxoSmith-Kline. Kassel joins Syrrx after previous positions as senior director of DuPont Pharmaceuticals Research Labs and director of analytical chemistry at CombiChem.
Judd Berman will join Affinium Pharmaceuticals as senior vice president for chemistry, the Toronto-based company said last week. Berman most recently served as director and site head of high- throughput chemistry at GlaxoSmithKline''''''''''''''''s Research Triangle Park, NC, facility. He has also held the position of interim site head for computational, analytical, and structural sciences for GSK.
Large Scale Biology Corporation has appointed Charles Nash to the company’s board of directors, replacing Leigh Anderson, who resigned from the board last month. Nash is the principal of Nash Equity Capital, a strategic corporate consulting practice in Atlanta.